Zinthionein™

Zinthionein™ (Oral ZMC) is an novel covalently linked form of zinc-monocysteine complex that has been developed by Dr. David Newsome, a leading clinical scientist and inventor of Ovuvite and Preservision, two marketed products for the treatment of AMD.

Age-Related Eye Disease Study (AREDS)

This proprietary molecule builds on the success of the Age-Related Eye Disease Study (AREDS), a randomized, placebo-controlled clinical trial funded by the National Eye Institute. AREDS evaluated over 4,757 patients between the ages of 55 and 80 for an average of 6.3 years. Scientists found that people at high risk of developing advanced stages of AMD, lowered their risk by approximately 25 percent when treated with a high-dose combination of anti-oxidants and zinc. In the same high risk group, which includes people with intermediate AMD, or advanced AMD in one eye but not the other eye, this combination reduced the risk of vision loss caused by advanced AMD by about 19 percent. The AREDS study also demonstrated that reduced vision in advanced AMD patients was also correlated to reduced cognitive function.

About Age Related Macular Degeneration (AMD)

Macular degeneration is a progressive eye condition affecting as many as 15 million Americans and millions more around the world. The disease attacks the macula of the eye, where our sharpest central vision occurs. Age Related Macular Degeneration (AMD) is the number one cause of vision loss and legal blindness in adults over 60 in the U.S. As our population ages, and the "baby boomers" advance into their 50's and 60's, we will see a virtual epidemic of AMD. Perhaps 14%-24% of the U.S. population aged 65-74 years and 35% of people aged 75 years or more have the disease.